Prescription drug monitoring programs, a response to doctor shopping: Purpose, effectiveness, and directions for future research

Issues in Mental Health Nursing

Volumn 33, Issue 5, 2012, Pages 319-328

  Worley, Julie ^a  

^a Private Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADDICTION; DRUG CONTROL; DRUG MONITORING; DRUG UTILIZATION; FACTUAL DATABASE; HUMAN; ORGANIZATION AND MANAGEMENT; REVIEW; STATISTICS; UNITED STATES;

DATABASES, FACTUAL; DRUG AND NARCOTIC CONTROL; DRUG MONITORING; DRUG UTILIZATION; HUMANS; PRESCRIPTION DRUGS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 84860456317     PISSN: 01612840     EISSN: 10964673     Source Type: Journal    
DOI: 10.3109/01612840.2011.654046     Document Type: Review

References (30)

1. American Medical Association. (2010). The state-level economic impact ofoffice-based physicians. Retrieved from http://www.ama-assn.org/resources/doc/ arc/economic-impact/economic-impact-report.pdf
2. Baehren, D. F., Marco, C. A., Droz, D. E., Sinha, S. S., Callan, E. M., &Akpunonu, B. S. (2010). A statewide prescriptionmonitoring program affectsemergency department prescribing behaviors. Annals ofEmergency Medicine,56(1), 19-23.
3. Barrett, K., &Watson, A. (2005). Physician perspectives on a pilot prescriptionmonitoring program. Journal of Pain & Palliative Care Pharmacotherapy,19(3), 5-13.
4. Civic Federation. (2009). Medicaid prescription drug abuse alleged in Illinoisand other states. Retrieved from http://www.civicfed.org/iifs/blog/ medicaidprescription-drug-abuse-alleged-illinois-and-other-states
5. Justia US Law. (2009). Iowa code title 4-public health subtitle 3-healthrelatedprofessions chapter 155A-pharmacy 155A.23-prohibited acts. Retrievedfrom http://law.justia.com/codes/iowa/2009/title-4/subtitle-3/chapter- 155a/155a-23/
6. Kaiser Family Foundation. (2011). United States: Total nurse practitioners,2010. Retrieved from http://www.statehealthfacts.org/profileind. jsp?ind =773&cat = 8&rgn = 1
7. Manchikanti, L., & Singh, A. (2008). Therapeutic opioids: A ten-year perspectiveon the complexities and complications of the escalating use, abuse, andnonmedical use of opioids. Pain Physician, 11, S63-S88.
8. National Alliance For Model State Drug Laws. (2011). Practitioner educationin the utilization prescription monitoring program data. Retrievedfrom http://www.namsdl.org/documents/PractitionerLiability-NatPMPMtg-6-8-11.pdf
9. National Institute on Drug Abuse. (n.d.) The basics: The science of drug use andaddiction. Retrieved from http://drugabuse.gov/mediaguide/scienceof.html
10. National Substance Abuse Index. (n.d.). Federal drug classification schedules.Retrieved from http://nationalsubstanceabuseindex.org/drugclass.htm
11. Office of Naional Drug Control Policy. (2006). Synthetic drug control strategy.Retrieved from http://dhs.alabama.gov/pdf/info/syntheticstrategy.pdf
12. Paulozzi, L. J., Kilbourne, E. M., & Desai, H. A. (2011). Prescription drugmonitoring programs and death rates from drug overdose. Pain Medicine, 12,747-754.
13. Pradel, V., Frauger, E., Thirion, X., Ronfle, E, Lapierre, V., Masut, A. L., Coudert,C., Blin, O., & Micallef, J. (2009). Impact of a prescription monitoringprogram on doctor-shopping for high dose buprenorphine. Pharmacoepidemiologyand Drug Safety, 18(1), 36-43.
14. Reisman, R. M., Shenoy, P. J., Atherly, A. J., & Flowers, C. R. (2009). Prescriptionopioid usage and abuse relationships: An evaluation of state prescriptiondrug monitoring program efficiency. Substance Abuse: Research and Treatment,3, 41-51.
15. Ross-Degnan, D., Simoni-Wastila, L., Brown, J. S., Gao, X., Mah, C., Cosler,L. E., Fanning, T., Gallagher, P., Salzman, C., Shader, R. I., Inui, T. S., &Soumerai, S. B. (2004). A controlled study of the effects of state surveillanceon indicators of problematic and non-problematic benzodiazepine use in aMedicaid population. International Journal of Psychiatry in Medicine, 34(2),103-123.
16. Simeone, R., & Holland, L. (2006). An evaluation of prescriptiondrug monitoring programs. Retrieved from http://pmpexcellence.org/pdfs/simeone pdmp eval2 2006.pdf
17. Simoni-Watsila, L., Ross-Degnan, D., Mah, C., Gao, X., Brown, J., Cosler, L.E., Fanning, T., Gallagher, P., Salzman, C., & Soumerai, S. B. (2004). A retrospectivedata analysis of the impact of the New York triplicate prescriptionprogram on benzodiazepine use in Medicaid patients with chronic psychiatricand neurologic disorders. Clinical Therapeutics, 26(2), 322-336.
18. Substance Abuse and Mental Health Services Administration. (2010). Resultsfrom the 2009 National Survey on Drug Use and Health: Volume I. Summaryof National Findings (HHS Publication No. SMA 10-4586). Rockville, MD:Office of Applied Studies.
19. Substance Abuse Policy Research Program. (no date) Policy brief: Substanceabuse benefits and costs. Retrieved from, http://www.saprp.org/ knowledgeassets/knowledgebrief.cfm?KAID = 1
20. Tennessee Medical Association. (2009). Doctor shopping in Tennessee: Aprescriber's responsibility under Tennessee law. Retrieved from http://www.tnmed.org/uploadedFiles/Stay Informed/Resources/Legal Resources/DocShopping.pdf
21. Ulbrich, T. R., Dula Clark, C. A., Green, C. G., Porter, K., & Bennett, M. S.(2010). Factors influencing community pharmacists' enrollment in a stateprescription monitoring program. Journal of the American Pharmacists Association,50(5), 588-594.
22. University of Kentucky Institute for Pharmaceutical Outcomes and Policy.(2010). Review of prescription drug monitoring programs. Retrieved fromhttp://chfs.ky.gov/NR/rdonlyres/85989824-1030-4AA6-91E1-7F9E3EF-68827/0/ KASPEREvaluationPDMP
23. StatusFinalReport6242010.pdfU.S. Center for Disease Control. (2010). Number of poisoning deaths involvingopioid analgesics and other drugs or substances-United States, 1999-2007. Morbidity and Mortality Weekly Report, 59(32), 1026.
24. U.S. Department of Health and Human Services. (2009). Cost offsetof treatment services. Retrieved from http://www.samhsa.gov/grants/CSAT-GPRA/ general/SAIS GPRA CostOffsetSubstanceAbuse.pdf
25. U.S. Department of Justice Drug Enforcement Agency. (no date). Controlledsubstance schedules. Retrieved from http://www.deadiversion.usdoj.gov/ schedules/
26. U.S. Department of Justice Drug Enforcement Agency (2009). Facts aboutprescription drug diversion and abuse. Retrieved from, http://www.justice. gov/dea/concern/prescription drug fact sheet.html.
27. U.S. Government Accountability Office. (2011). Medicare Part D: Instancesof questionable access to prescription drugs. Retrieved fromhttp://www.scribd.com/doc/67614641/GAO-Report-on-Medicare-Part-D
28. Wang, J. & Christo, P. J. (2009). The influence of prescription monitoringprograms on chronic pain management. Pain Physician, 12, 507-515.
29. Wilsey, B. L., Fishman, S. M., Gilson, A. M., Casamalhuapa, C., Baxi, H.,Lin, T. S., & Li, C. S. (2011). An analysis of the number of multiple prescribersfor opioids utilizing data from the California prescription monitoringprogram. Pharmacoepidemiology and Drug Safety. doi: 10.1002/pds.2129
30. Wilsey, B. L., Fishman, S. M., Gilson, A. M., Casamalhuapa, C., Baxi, H.,Zhang, H., & Li, C. S. (2010). Profiling multiple provider prescribing ofopioids, benzodiazepines, stimulants, and anorexics. Drug and Alcohol Dependence,112(1-2), 99-106.